
Novo Nordisk is looking into a growth-heavy Q2, as it has had tailwind with diabetes 2 drugs Ozempic and Rybelsus, and as the demand is high for its new weight-loss treatment Wegovy.
The results appear extra positive, when compared with the second quarter of last year. In the first quarter of 2020, as the covid-19 crisis was starting, patients began to stockpile medicine, after which growth receded for a while.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app